Recent developments in the management of psychosis.
Antipsychotic drugs are effective in psychoses, whatever the aetiology of the disorder. The positive symptoms tend to respond more readily. The need for developing new drugs arises from the refractoriness of the negative symptoms, the 10-25% of the patients that are treatment-resistant and the problems of short-, and long-term extrapyramidal side-effects. Thus far, five drugs differing from the classical antipsychotics have been licensed for use: clozapine, olanzepine, risperidone, sertindole and sulpiride, and in at least some European countries quetiapine is now in the final phase of clinical research. This review starts with a brief introduction to symptomatology, is limited to the registered drugs and addresses differences with the classical drugs in pharmacology, pharmacokinetics, clinical aspects and side-effects. Clozapine, risperidone and sulpiride can be considered for clinical use in refractory patients, and these three together with olanzapine and sertindole are candidates when extrapyramidal side-effects cause a clinical problem.
Hoes
M J
MJ
Department of Psychiatry, Ziekenhuis Rivierenland, Tiel, The Netherlands.
D014150:Antipsychotic Agents / Q000145:classification / Q000627:therapeutic use*; D003024:Clozapine / Q000008:administration & dosage / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D013469:Sulpiride / Q000008:administration & dosage / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D012702:Serotonin Antagonists; D013469:Sulpiride; D003024:Clozapine; D018967:Risperidone